中老年活动性大动脉炎患者的临床特征分析
回顾性纳入2017—2025年北京朝阳医院首次确诊的106例大动脉炎患者,其中年龄>50岁者11例(男2例、女9例)。中老年活动性TAK占同期10.40%,中位诊断年龄61岁,诊断延迟中位13个月,肺动脉受累常见,中老年男性病情可能更重。
要点
- 中老年活动性TAK占同期首次确诊TAK的10.40%(11/106),中位诊断年龄61岁。
- 以呼吸症状为主者应完善CTPA、MRPA以明确肺动脉受累。
- 中老年男性TAK患者病情严重程度可能更重,需全面评价动脉受累。
核心结论
- 活动性TAK可出现在年龄>60岁人群,中老年男性患者病情严重程度可能更重。
- 中老年活动性TAK需用超声等手段全面评价动脉情况,以提升鉴别诊断能力。
- 以呼吸系统症状为主就诊者应注重完善CTPA、MRPA以明确肺动脉受累。
研究设计与样本
- 回顾性收集2017—2025年首都医科大学附属北京朝阳医院首次确诊TAK患者106例的临床资料。
- 纳入年龄>50岁的TAK患者11例,其中男2例、女9例,均至少随访1次。
主要发现
- 中老年活动性TAK占同期首次确诊TAK的10.40%(11/106),中位诊断年龄61岁,>60岁者6例(6/11)。
- 从发病到确诊的中位时间为13(12,36)个月。
- 11例均存在多个动脉支受累,但均未完整评价国际标准涵盖的所有动脉。
- 8例行CTPA或胸部增强CT者均存在肺动脉管腔狭窄;8例行MRPA者均存在肺动脉管壁增厚伴强化、管腔狭窄。
- 9例行PET-CT者中7例肺动脉呈高代谢。
关键数值与推荐
- 多种自身抗体水平升高的4例中,男2例(2/2)、女2例(2/9)。
- 2例男性患者均出现严重TAK相关并发症(1例腹主动脉瘤、1例肺动脉高压)。
临床怎么用
- 对中老年活动性TAK患者应用超声等手段全面评价动脉受累情况。
- 以呼吸系统症状为主就诊的患者应完善CTPA、MRPA以明确肺动脉受累。
局限性
- 本研究为单中心回顾性研究,中老年活动性TAK样本量仅11例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To draw attention to the diagnosis of active Takayasu arteritis (TAK) in middle-aged and elderly patients and to analyze the clinical characteristics of this population. Methods: Clinical data of 106 patients newly diagnosed with TAK at Beijing Chao-Yang Hospital, Capital Medical University, between 2017 and 2025 were retrospectively collected; 11 patients aged over 50 years (2 men and 9 women) were enrolled in this study. Onset characteristics, medical history, clinical manifestations, laboratory findings, and imaging features were collected and analyzed. Disease activity was evaluated, treatment regimens and prognosis were recorded, and all patients underwent at least one follow-up. Results: Among patients first diagnosed with TAK at this single center, middle-aged and elderly patients with active TAK accounted for 10.40% (11/106) during the same period, with a median age at diagnosis of 61 years. Among them, 6 patients (6/11) were over 60 years old. The median time from symptom onset to diagnosis was 13 months (interquartile range: 12, 36 months). Although all 11 patients had multiple arterial involvements, none underwent complete evaluation of all arteries covered by the international criteria. Among the 8 patients who underwent CT pulmonary angiography (CTPA) or chest contrast-enhanced CT, all showed pulmonary artery luminal stenosis. All 8 patients who underwent contrast-enhanced magnetic resonance pulmonary angiography (MRPA) exhibited pulmonary artery wall thickening with enhancement and luminal stenosis. Of the 9 patients who underwent PET-CT, 7 showed pulmonary artery hypermetabolism. Among the 4 patients with elevated levels of multiple autoantibodies, 2 were male (2/2) and 2 were female (22.2% of female patients, 2/9). Moreover, both male patients had severe TAK-related complications (one with an abdominal aortic aneurysm and the other with pulmonary hypertension). Conclusion: Active TAK can occur in individuals over 60 years of age and the disease may be more severe in middle-aged and elderly male TAK patients. Middle-aged and elderly patients with active TAK require comprehensive evaluation of arterial involvement with modalities such as ultrasound, so as to enhance the capability of clinical differential diagnosis. For patients presenting primarily with respiratory symptoms, CTPA and MRPA should be performed to clarify pulmonary artery involvement in TAK. 目的: 关注中老年活动性大动脉炎(TAK)的诊断,分析此类患者临床特点。 方法: 回顾性收集2017—2025年首都医科大学附属北京朝阳医院首次确诊TAK的患者资料106例,纳入其中年龄>50岁的TAK患者11例,其中男2例,女9例。采集并分析其发病特点、病史、临床表现、实验室检查、影像学特征,评估TAK活动性,记录治疗方案及预后,并对患者进行至少1次随访。 结果: 在单中心首次确诊的TAK患者中,中老年活动性TAK占同期的10.40%(11/106),中位诊断年龄61岁,>60岁的患者6例(6/11)。从发病到确诊的中位时间13(12,36)个月。尽管11例患者均存在多个动脉支受累,但所有患者都未能完整评价国际标准涵盖的所有动脉。8例患者完善CT肺动脉造影(CTPA)或胸部增强CT,均存在肺动脉管腔狭窄;8例行肺动脉增强核磁(MRPA)均存在肺动脉管壁增厚伴强化、管腔狭窄;9例行PET-CT,其中7例肺动脉呈高代谢。在多种自身抗体水平升高的4例患者中,男2例(2/2)、女2例(2/9),并且2例男性患者均出现严重TAK相关并发症(1例腹主动脉瘤、1例肺动脉高压)。 结论: 活动性TAK可以出现在年龄>60岁的人群中,中老年男性TAK患者的病情严重程度可能更重。中老年活动性TAK患者需要应用超声等手段全面评价动脉情况,提升临床鉴别诊断的能力;以呼吸系统症状为主就诊的患者,应注重完善CTPA、MRPA以明确TAK肺动脉受累情况。.
引用
- Guo CN, Yang SQ, Guo XJ, et al. [Clinical characteristics of middle-age and elderly patients with active Takayasu arteritis disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42373448. doi:10.3760/cma.j.cn112147-20260112-00021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。